MX351230B - Formulacion oftalmica y metodo para mitigar la presbicia. - Google Patents

Formulacion oftalmica y metodo para mitigar la presbicia.

Info

Publication number
MX351230B
MX351230B MX2015000806A MX2015000806A MX351230B MX 351230 B MX351230 B MX 351230B MX 2015000806 A MX2015000806 A MX 2015000806A MX 2015000806 A MX2015000806 A MX 2015000806A MX 351230 B MX351230 B MX 351230B
Authority
MX
Mexico
Prior art keywords
ophthalmic formulation
presbyopia
disclosed
ameliorating
ameliorating presbyopia
Prior art date
Application number
MX2015000806A
Other languages
English (en)
Other versions
MX2015000806A (es
Inventor
Restrepo Luis Felipe Vejarano
Original Assignee
Restrepo Luis Felipe Vejarano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Restrepo Luis Felipe Vejarano filed Critical Restrepo Luis Felipe Vejarano
Publication of MX2015000806A publication Critical patent/MX2015000806A/es
Publication of MX351230B publication Critical patent/MX351230B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describe una formulación oftálmica que tiene una cantidad efectiva de un agente parasimpaticomimético que comprende pilocarpina, o una sal farmacéuticamente aceptable de la misma, y uno o más agonistas o antagonistas a1 adrenérgicos. La formulación oftálmica puede permitir el tratamiento de condiciones que afectan de manera adversa la agudeza visual de un paciente, incluyendo presbicia. También se describe un método para utilizar la formulación oftálmica descrita para tratar o mitigar los síntomas de la presbicia.
MX2015000806A 2012-07-19 2013-07-18 Formulacion oftalmica y metodo para mitigar la presbicia. MX351230B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/553,615 US10507245B2 (en) 2012-07-19 2012-07-19 Ophthalmic formulation and method for ameliorating presbyopia
PCT/US2013/051153 WO2014015183A1 (en) 2012-07-19 2013-07-18 Ophthalmic formulation and method for ameliorating presbyopia

Publications (2)

Publication Number Publication Date
MX2015000806A MX2015000806A (es) 2015-08-10
MX351230B true MX351230B (es) 2017-10-06

Family

ID=48917698

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000806A MX351230B (es) 2012-07-19 2013-07-18 Formulacion oftalmica y metodo para mitigar la presbicia.

Country Status (15)

Country Link
US (2) US10507245B2 (es)
EP (1) EP2874660B1 (es)
CN (2) CN104717981A (es)
AR (2) AR092860A1 (es)
BR (1) BR112015001158B1 (es)
CO (1) CO7250451A2 (es)
DK (1) DK2874660T3 (es)
ES (1) ES2719250T3 (es)
HR (1) HRP20190627T1 (es)
MX (1) MX351230B (es)
PL (1) PL2874660T3 (es)
PT (1) PT2874660T (es)
RU (1) RU2657514C2 (es)
TR (1) TR201905683T4 (es)
WO (1) WO2014015183A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2630968C2 (ru) 2011-09-20 2017-09-15 Аллерган, Инк. Лекарственные средства и способы лечения пресбиопии, умеренной гиперметропии и неправильного астигматизма
ES2538551B1 (es) * 2013-12-20 2016-01-13 Eurocanarias Oftalmológica, Sl Composición Oftálmica para la corrección de la presbicia
CA2939427A1 (en) * 2014-02-11 2015-08-20 Vid D.O.O. Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration
CN104856990A (zh) * 2015-05-07 2015-08-26 武汉武药科技有限公司 去氧肾上腺素酮咯酸溶液及制备方法
US20190000808A1 (en) * 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
CH711969A2 (it) * 2015-12-29 2017-06-30 Pinelli Roberto Composizione per il trattamento della presbiopia.
CN116726006A (zh) 2016-08-19 2023-09-12 阿拉西斯医药公司 眼科药物组合物及其相关用途
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
EP3749303A4 (en) * 2018-02-05 2022-01-26 Cellixbio Private Limited COMBINATION OF ANTIMUSCARINIC AGENT OR ANTICHOLINERGIC AGENT AND LIPOIC ACID AND USES THEREOF
WO2019204401A1 (en) * 2018-04-19 2019-10-24 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
WO2019209955A2 (en) 2018-04-24 2019-10-31 Allergan, Inc. Presbyopia treatments
JP2021534217A (ja) * 2018-08-21 2021-12-09 アラーガン、インコーポレイテッドAllergan, Incorporated 視力を改善するためのａ−２−アドレナリン受容体アゴニストの使用
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
SG11202104094YA (en) 2018-10-26 2021-05-28 Ocuphire Pharma Inc Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
US11071724B2 (en) * 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
AU2020290998A1 (en) * 2019-06-10 2022-01-20 Visus Therapeutics, Inc. Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
MX2020012116A (es) * 2020-11-12 2022-08-09 Cesar Alejandro Sanchez Galeana Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia.
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
CN116350790A (zh) * 2021-12-28 2023-06-30 沈阳兴齐眼药股份有限公司 组合物及其在制备用于治疗老花眼的药物中的用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
DK335086A (da) 1985-08-05 1987-02-06 Michele Testa Kemiske sammensaetninger og farmaceutiske praeparater til topisk brug indeholdende mindst en af de kemiske sammensaetninger i en terapeutiskvirksom maengde
US4902696A (en) * 1987-10-08 1990-02-20 Hoechst-Roussel Pharmaceuticals, Inc. Synergistic intraocular pressure lowering combinations
US5192780A (en) * 1989-12-18 1993-03-09 Alcon Laboratories, Inc. Methods using antiallergics and antihistamines
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5624962A (en) 1993-04-16 1997-04-29 Wakamoto Pharmaceutical Co., Ltd. Aqueous drug composition having property of reversible thermosetting gelation
US5677321A (en) 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
IT1306135B1 (it) * 1999-04-26 2001-05-30 Farmigea Spa Composizioni oftalmiche per il trattamento delle turbe visivecaratterizzate da ridotta sensibilita' al contrasto.
US20050261641A1 (en) 2002-09-26 2005-11-24 Warchol Mark P Method for ophthalmic administration of medicament
WO2004058289A1 (en) 2002-12-20 2004-07-15 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
US20060166879A1 (en) 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
US20060172972A1 (en) 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US20060177430A1 (en) 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US7252662B2 (en) 2004-11-02 2007-08-07 Lenticular Research Group Llc Apparatus and processes for preventing or delaying one or more symptoms of presbyopia
DE602006008643D1 (de) 2006-12-18 2009-10-01 Jorge Luis Benozzi Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie
GB0724558D0 (en) * 2007-12-15 2008-01-30 Sharma Anant Optical correction
TNSN08110A1 (en) 2008-03-11 2009-07-14 Rekik Raouf Dr Drug delivery to the anterior and posterior segment of the eye from drops
TWI542338B (zh) 2008-05-07 2016-07-21 壯生和壯生視覺關懷公司 用於活性劑之控制釋放的眼用裝置
WO2010125416A1 (en) 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
US8299079B2 (en) * 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US20100298335A1 (en) 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
WO2011064631A1 (en) 2009-10-02 2011-06-03 Foamix Ltd. Surfactant-free, water-free, foamable compositions and breakable foams and their uses
WO2011075481A1 (en) 2009-12-16 2011-06-23 Allergan, Inc. Intracameral devices for sustained delivery
US20110301555A1 (en) 2010-06-03 2011-12-08 Gonzalez-Zugasti Javier P Porous matrix drug core for lacrimal insert device
US20120003296A1 (en) 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
RU2630968C2 (ru) * 2011-09-20 2017-09-15 Аллерган, Инк. Лекарственные средства и способы лечения пресбиопии, умеренной гиперметропии и неправильного астигматизма

Also Published As

Publication number Publication date
WO2014015183A1 (en) 2014-01-23
CN113425715A (zh) 2021-09-24
AR121843A2 (es) 2022-07-13
BR112015001158A2 (pt) 2017-06-27
EP2874660A1 (en) 2015-05-27
US20200237916A1 (en) 2020-07-30
PL2874660T3 (pl) 2019-07-31
PT2874660T (pt) 2019-05-14
HRP20190627T1 (hr) 2019-06-14
US10507245B2 (en) 2019-12-17
CO7250451A2 (es) 2015-04-30
CN104717981A (zh) 2015-06-17
TR201905683T4 (tr) 2019-05-21
DK2874660T3 (en) 2019-04-15
AR092860A1 (es) 2015-05-06
ES2719250T3 (es) 2019-07-09
US20140024642A1 (en) 2014-01-23
BR112015001158B1 (pt) 2020-12-15
MX2015000806A (es) 2015-08-10
EP2874660B1 (en) 2019-01-23
RU2015102531A (ru) 2016-09-10
RU2657514C2 (ru) 2018-06-14

Similar Documents

Publication Publication Date Title
MX351230B (es) Formulacion oftalmica y metodo para mitigar la presbicia.
MY171920A (en) Prevention and treatment of ocular conditions
MX2019004468A (es) Uso de lentes de contacto en el tratamiento de una afeccion oftalmologica.
UA111959C2 (uk) Застосування лаквінімоду для зменшення втоми, поліпшення функціонального стану та поліпшення якості життя у пацієнтів з розсіяним склерозом
MY170198A (en) Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
NZ704247A (en) Compositions and treatment for eye diseases and disorders
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
EA201690212A1 (ru) Способы лечения или профилактики офтальмологических патологических состояний
MX337614B (es) Tratamiento de lupus nefritis usando laquinimod.
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
IL227412A (en) Administration of cross-materials to corne by iontophoresis for the treatment of keratoconus and ophthalmic preparations for this purpose
MA33991B1 (fr) Procede de traitement des troubles de l'angiogenese oculaire ou de la fuite vasculaire
MY165160A (en) TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS
MX2014005209A (es) Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retencion de lagrimas.
WO2011116020A3 (en) Ophthalmic formulations of cetirizine and methods of use
NZ704178A (en) Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
IN2013DE03085A (es)
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX370451B (es) Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi metil)-naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.
MX2016006256A (es) Tratamiento de glaucoma usando laquinimod.

Legal Events

Date Code Title Description
FG Grant or registration